Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated 1.4 billion people worldwide, including 64 million people in the United ...

Eli Lilly experienced a 6% increase in price over ... levels, a genetic heart disease risk factor. Additionally, the company's expansion in digital healthcare and strategic partnerships, like ...

Eli Lilly And Co (NYSE:LLY), on Sunday ... [Lp(a)], a genetically inherited risk factor for heart disease. In the Phase 2 ALPACA study, lepodisiran significantly reduced Lp(a) levels by an ...

Eli Lilly (NYSE:LLY) released positive Phase 2 ... The trial results showed 94% lower levels of a genetically inherited heart disease risk factor in adults with elevated risk taking the highest ...

CHICAGO (Reuters) - The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk factor for heart disease in a midstage trial ...

New tools to connect with independent in-person and telehealth providers specializing in Alzheimer's disease are designed to increase capacity and reduce delays in diagnosis INDIANAPOLIS, March 27, ...

CHICAGO (Reuters) - The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk factor for heart disease in a midstage trial, according ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

Experimental Lilly Drug Cuts Genetic Heart Disease Risk Factor by 94% in Trial By Julie Steenhuysen CHICAGO (Reuters) - The highest dose of an experimental drug developed by Eli Lilly ...